Adverse Event Management in Colorectal Cancer: Optimizing Treatment Approaches in the 3L Setting - Episode 11

Toxicity Considerations and Treatment Decisions in CRC

, , ,

Experts on colorectal cancer discuss the treatment decision-making process, highlighting the safety profiles of fruquintinib and regorafenib.

EP. 1: Adverse Event Management in Colorectal Cancer: Optimizing Treatment Approaches in the 3L Setting
EP. 2: Selecting Optimal 3L Colorectal Cancer Treatment
EP. 3: Patient Case 1: 46-Year-Old Woman with Prior Hx of MSS pT4aN1b Rectosigmoid Colon Adenocarcinoma s/p Prior Treatment
EP. 4: General Approach to 3L CRC Treatment with TAS-102 + Bevacizumab
EP. 5: Adverse Events Associated With TAS-102 Plus Bevacizumab in CRC
EP. 6: Patient Case 2: A 62-Year-Old Woman with Metastatic Rectal Cancer
EP. 7: Treatment Considerations With Regorafenib in Colorectal Cancer
EP. 8: Patient Case 3: A 57-Year-Old Man With Cecal Colon Adenocarcinoma
EP. 9: FRESCO-2: Fruquintinib in Patients with Refractory Metastatic CRC
EP. 10: Monitoring and AE Management Strategies with Fruquintinib in CRC
Now Viewing
EP. 11: Toxicity Considerations and Treatment Decisions in CRC
EP. 12: Multidisciplinary Care for Patients with CRC
EP. 13: Unmet Needs and Future Perspectives in Colorectal Cancer